Harpoon Therapeutics (HARP) Stock Price, News & Analysis

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HARP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HARP, but not buy additional shares or sell existing shares.
View HARP analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued twelve-month target prices for Harpoon Therapeutics' stock. Their HARP share price targets range from $23.00 to $40.00. On average, they predict the company's share price to reach $27.25 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for HARP or view top-rated stocks among Wall Street analysts.

Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its quarterly earnings results on Monday, March, 27th. The company reported ($5.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.70) by $0.80. The firm earned $4.09 million during the quarter, compared to analyst estimates of $11.06 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 893.55% and a negative net margin of 81.68%.

AltShares Merger Arbitrage ETF holds 52,182 shares of HARP stock, representing 1.96% of its portfolio.

Harpoon Therapeutics shares reverse split before market open on Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

Harpoon Therapeutics (HARP) raised $76 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.